

LAB ALERT: Respiratory Pathogen Panel to now include COVID-19 and *Bordetella parapertussis*

Date: July 23, 2020

Dear Regional Pathology Services Clients,

We are very excited to announce that effective July 16, 2020 we have begun offering the Respiratory Pathogen Panel that now includes the SARS CoV-2 causing COVID19.

The BioFire respiratory panel 2.1 (RP2.1) is an FDA-approved multiplex PCR panel that can be used to identify 22 bacterial and viral pathogens. In comparison to our current respiratory panel, this panel detects SARS CoV-2 causing COVID19 and *Bordetella parapertussis*. **However, due to the limited quantity of panels available, the RP2.1 should not be used as a primary COVID19 diagnostic.** Instead, the RP2.1 should be reserved for use in populations where knowledge of specific viral pathogens has clinical impact (i.e. RSV or Parainfluenza in stem cell transplant patient) or there is significant diagnostic uncertainty (i.e. atypical pneumonia not responding to antibiotics). **Note this diagnostic approach may change during influenza season depending on a variety of factors including the development of other platforms that rapidly identify both influenza and SARS CoV-2.**

Guidelines for RP2.1 use during the COVID19 pandemic:

- Patients with symptoms concerning for COVID-19 should be tested for SARS-CoV-2 using our current COVID-19 PCR test (Test code: COV19)
- For patients where there is strong suspicion for other respiratory pathogens or where COVID testing is negative the RP2.1 may be considered
- The RPP is adequately sensitive for SARS-CoV-2 and can be used in the process of ruling out COVID19 if needed, although testing using the current SARS-CoV-2 testing platform (COV19) is strongly preferred. The determination of the need for 1 or 2 COVID tests should follow current protocols.
- Patients who have been tested with the RPP should not be retested for at least 7 days.
- Asymptomatic patients should **NOT** be tested using the RPP including pre-procedural and admission-based screening. Screening for COVID-19 should be done using the current SARS-CoV-2 tests (COV19).

Source: Nasopharyngeal swab in viral transport media. Note: BAL is no longer an accepted source for the respiratory panel.

Test Name: [Respiratory pathogen panel by PCR \(viral/bacterial\)](#)

Test Code: RESPP

Below are the pathogens included in the panel and the Interface Build Info. Please note that the CPT code has changed from PLA 0099U to PLA 0202U. Client fees remain the same. New pathogens added are highlighted in the table below.

OrderCode	OrderName	ResultCode	ResultName	ResultUnits	LOINC	CPT
RESPP	RESP PATH PANEL PCR	ADEN	ADENOVIRUS		82160-3	0202U
RESPP	RESP PATH PANEL PCR	CV229E	CORONAVIRUS 229E		82163-7	

REGIONAL PATHOLOGY SERVICES

RESPP	RESP PATH PANEL PCR	CVHKU1	CORONAVIRUS HKU1		82161-1	
RESPP	RESP PATH PANEL PCR	CVNL63	CORONAVIRUS NL63		82162-9	
RESPP	RESP PATH PANEL PCR	CVOC43	CORONAVIRUS OC43		82164-5	
RESPP	RESP PATH PANEL PCR	SARSV2	SARS-CoV-2		94565-9	
RESPP	RESP PATH PANEL PCR	HMETAP	METAPNEUMOVIRUS		82165-2	
RESPP	RESP PATH PANEL PCR	HRHENT	RHINOVIRUS/ENTEROVIRUS		82175-1	
RESPP	RESP PATH PANEL PCR	IVA	INFLUENZA TYPE A		82166-0	
RESPP	RESP PATH PANEL PCR	IV2009	INFLU 2009A-H1N1v		82168-6	
RESPP	RESP PATH PANEL PCR	IVAH1	INFLU A SUBTYPE H1		82167-8	
RESPP	RESP PATH PANEL PCR	IVAH3	INFLU A SUBTYPE H3		82169-4	
RESPP	RESP PATH PANEL PCR	IVB	INFLUENZA TYPE B		82170-2	
RESPP	RESP PATH PANEL PCR	PARAV1	PARAINFLUENZA 1		82171-0	
RESPP	RESP PATH PANEL PCR	PARAV2	PARAINFLUENZA 2		82172-8	
RESPP	RESP PATH PANEL PCR	PARAV3	PARAINFLUENZA 3		82173-6	
RESPP	RESP PATH PANEL PCR	PARAV4	PARAINFLUENZA 4		82174-4	
RESPP	RESP PATH PANEL PCR	RESYV	RESP SYNCYTIAL VIRUS		82176-9	
RESPP	RESP PATH PANEL PCR	BORPER	BORDETELLA PERTUSSIS		82179-3	
RESPP	RESP PATH PANEL PCR	BORPAR	BORDETELLA PARAPERTUSSIS (IS1001)		87621-9	
RESPP	RESP PATH PANEL PCR	CHLPNE	CHLAMYDOPHILA PNEUMONIAE		82178-5	
RESPP	RESP PATH PANEL PCR	MYCPNE	MYCOPLASMA PNEUMONIAE		82177-7	
RESPP	RESP PATH PANEL PCR	RVPSRC	Source		31208-2	
RESPP	RESP PATH PANEL PCR	RVPCOM	Comment			

State reporting requirements are now requiring the AOE's (Ask at order entry) questions below to be included on any COVID-19 test. This takes effect 8/1/20. We ask that clients please include this information and build in their interfaces if applicable.

AOES:

Order Code	Order Description	AOE Code	AOE Name	Answer	Answer code	Question Type
RESP P	RESP PATH PANEL PCR	RVPSRC	Source			Freetext
		COVTST	First Test	Yes	YES	List
				No	NO	
				Unknown	U	
		COVEMP	Healthcare employee	Yes	YES	List
				No	NO	
				Unknown	U	
		COVSYM	Symptomatic per CDC	Yes	YES	List
				No	NO	
				Unknown	U	
		COVDAT	Symptom onset date			Date/Time MMDDYYYY
				Unknown	U	
		COVHOS	Hospitalized	Yes	YES	List
				No	NO	
				Unknown	U	
		COVICU	In ICU	Yes	YES	List
				No	NO	
				Unknown	U	
		COVCON	Resident in congregate care setting	Yes	YES	List
				No	NO	
				Unknown	U	

If you have any questions please contact client services at 402-559-6420. For technical questions please contact Kathie Rogers, PhD (402-552-3313, katrogers@nebraskamed.com) or Paul D. Fey, PhD (phone 402-559-2122, pager 402-888-5626, email: pfey@unmc.edu)